Cargando…
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
PURPOSE: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We us...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503521/ https://www.ncbi.nlm.nih.gov/pubmed/37719133 http://dx.doi.org/10.2147/CEOR.S412079 |
_version_ | 1785106538877157376 |
---|---|
author | Gertz, Morie Abonour, Rafat Gibbs, Sarah N Finkel, Muriel Landau, Heather Lentzsch, Suzanne Lin, Grace Mahindra, Anuj Quock, Tiffany Rosenbaum, Cara Rosenzweig, Michael Sidana, Surbhi Tuchman, Sascha A Witteles, Ronald Yermilov, Irina Broder, Michael S |
author_facet | Gertz, Morie Abonour, Rafat Gibbs, Sarah N Finkel, Muriel Landau, Heather Lentzsch, Suzanne Lin, Grace Mahindra, Anuj Quock, Tiffany Rosenbaum, Cara Rosenzweig, Michael Sidana, Surbhi Tuchman, Sascha A Witteles, Ronald Yermilov, Irina Broder, Michael S |
author_sort | Gertz, Morie |
collection | PubMed |
description | PURPOSE: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among advanced and non-advanced AL amyloidosis patients. PATIENTS AND METHODS: Using the RAND/UCLA modified Delphi method, expert panelists completed 180 healthcare utilization estimates, consisting of inpatient and outpatient visits, testing, chemotherapy, and procedures by disease severity and organ involvement during two treatment phases (the 1 year after starting first line [1L] therapy and 1 year following treatment [post-1L]). Estimates were also provided for post-1L by hematologic treatment response (complete or very good partial response [CR/VGPR], partial, no response or relapse [PR/NR/R]). Areas of disagreement were discussed during a meeting, after which ratings were completed a second time. RESULTS: During 1L therapy, 55% of advanced patients had ≥1 hospitalization and 38% had ≥2 admissions. Rates of hematopoietic stem cell transplant (HSCT) in advanced patients were 5%, while pacemaker or implantable cardioverter defibrillator (ICD) placement were 15%. During post-1L therapy, rates of hospitalization in advanced patients remained high (≥1 hospitalization: 20-43%, ≥2 hospitalizations: 10-20%), and up to 10% of advanced patients had a HSCT. Ten percent of these patients underwent pacemaker/ICD placement. CONCLUSION: Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new treatment options that can facilitate organ recovery and improve function may lead to decreased utilization. |
format | Online Article Text |
id | pubmed-10503521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105035212023-09-16 Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis Gertz, Morie Abonour, Rafat Gibbs, Sarah N Finkel, Muriel Landau, Heather Lentzsch, Suzanne Lin, Grace Mahindra, Anuj Quock, Tiffany Rosenbaum, Cara Rosenzweig, Michael Sidana, Surbhi Tuchman, Sascha A Witteles, Ronald Yermilov, Irina Broder, Michael S Clinicoecon Outcomes Res Short Report PURPOSE: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among advanced and non-advanced AL amyloidosis patients. PATIENTS AND METHODS: Using the RAND/UCLA modified Delphi method, expert panelists completed 180 healthcare utilization estimates, consisting of inpatient and outpatient visits, testing, chemotherapy, and procedures by disease severity and organ involvement during two treatment phases (the 1 year after starting first line [1L] therapy and 1 year following treatment [post-1L]). Estimates were also provided for post-1L by hematologic treatment response (complete or very good partial response [CR/VGPR], partial, no response or relapse [PR/NR/R]). Areas of disagreement were discussed during a meeting, after which ratings were completed a second time. RESULTS: During 1L therapy, 55% of advanced patients had ≥1 hospitalization and 38% had ≥2 admissions. Rates of hematopoietic stem cell transplant (HSCT) in advanced patients were 5%, while pacemaker or implantable cardioverter defibrillator (ICD) placement were 15%. During post-1L therapy, rates of hospitalization in advanced patients remained high (≥1 hospitalization: 20-43%, ≥2 hospitalizations: 10-20%), and up to 10% of advanced patients had a HSCT. Ten percent of these patients underwent pacemaker/ICD placement. CONCLUSION: Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new treatment options that can facilitate organ recovery and improve function may lead to decreased utilization. Dove 2023-09-11 /pmc/articles/PMC10503521/ /pubmed/37719133 http://dx.doi.org/10.2147/CEOR.S412079 Text en © 2023 Gertz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Short Report Gertz, Morie Abonour, Rafat Gibbs, Sarah N Finkel, Muriel Landau, Heather Lentzsch, Suzanne Lin, Grace Mahindra, Anuj Quock, Tiffany Rosenbaum, Cara Rosenzweig, Michael Sidana, Surbhi Tuchman, Sascha A Witteles, Ronald Yermilov, Irina Broder, Michael S Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis |
title | Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis |
title_full | Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis |
title_fullStr | Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis |
title_full_unstemmed | Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis |
title_short | Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis |
title_sort | using a modified delphi panel to estimate health service utilization for patients with advanced and non-advanced systemic light chain amyloidosis |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503521/ https://www.ncbi.nlm.nih.gov/pubmed/37719133 http://dx.doi.org/10.2147/CEOR.S412079 |
work_keys_str_mv | AT gertzmorie usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT abonourrafat usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT gibbssarahn usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT finkelmuriel usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT landauheather usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT lentzschsuzanne usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT lingrace usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT mahindraanuj usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT quocktiffany usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT rosenbaumcara usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT rosenzweigmichael usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT sidanasurbhi usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT tuchmansaschaa usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT wittelesronald usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT yermilovirina usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis AT brodermichaels usingamodifieddelphipaneltoestimatehealthserviceutilizationforpatientswithadvancedandnonadvancedsystemiclightchainamyloidosis |